Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Allison P. Jacob"'
Autor:
Daniel Branstetter, Kathy Rohrbach, Li-Ya Huang, Rosalia Soriano, Mark Tometsko, Michelle Blake, Allison P. Jacob, William C. Dougall
Publikováno v:
Journal of Bone Oncology, Vol 4, Iss 3, Pp 59-68 (2015)
Receptor activator of nuclear factor kappa-B ligand (RANKL) is an essential mediator of osteoclast formation, function and survival. In patients with solid tumor metastasis to the bone, targeting the bone microenvironment by inhibition of RANKL using
Externí odkaz:
https://doaj.org/article/18f9632d263c4179a834da9db4832412
Autor:
William C. Fanslow, Kim C. Quon, Matthew M. Bio, Margaret F. Weidner, Wesley S. Chang, Jason W. O'Neill, Christopher J. Borths, Dan A. Rock, Seamus P. Ragan, Sophia Siu, Robert R. Milburn, Sonal K. Patel, Brooke M. Rock, Mark E. Tometsko, Jesse L. Gurgel, Allison P. Jacob, Kevin J. Hamblett
Genes identified as critical for CD70 ADC function in Library 1 screen (S1); Genes identified as critical for CD70 ADC function in Library 2 screen (S2).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3afd7b980e59ed2ae74732dbadbd5224
https://doi.org/10.1158/0008-5472.22406852
https://doi.org/10.1158/0008-5472.22406852
Autor:
William C. Fanslow, Kim C. Quon, Matthew M. Bio, Margaret F. Weidner, Wesley S. Chang, Jason W. O'Neill, Christopher J. Borths, Dan A. Rock, Seamus P. Ragan, Sophia Siu, Robert R. Milburn, Sonal K. Patel, Brooke M. Rock, Mark E. Tometsko, Jesse L. Gurgel, Allison P. Jacob, Kevin J. Hamblett
Predicted topology for SLC46A3 (S1); Effect of siRNA on mRNA expression of SLC46A3 and CD70 in 786-0 cells (S2); Effect of siRNA on CD70 protein expression in 786-0 cells (S3); Anti-CD70 Ab-DSG-Maytansine and anti-CD70 Ab-Cys-Maytansine are potent ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3eff3eb212c549f79dc7834903550168
https://doi.org/10.1158/0008-5472.22406858.v1
https://doi.org/10.1158/0008-5472.22406858.v1
Autor:
William C. Fanslow, Kim C. Quon, Matthew M. Bio, Margaret F. Weidner, Wesley S. Chang, Jason W. O'Neill, Christopher J. Borths, Dan A. Rock, Seamus P. Ragan, Sophia Siu, Robert R. Milburn, Sonal K. Patel, Brooke M. Rock, Mark E. Tometsko, Jesse L. Gurgel, Allison P. Jacob, Kevin J. Hamblett
Description of additional methods and procedures used in the study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33716785c78c5ac8ae1ee739e76fa395
https://doi.org/10.1158/0008-5472.22406855.v1
https://doi.org/10.1158/0008-5472.22406855.v1
Autor:
Colette Owens, Allison P. Jacob, Jade Ruiters, Sidney Sechio, Audrey Hamilton, Clare Grieve, Puja Chadha, Mikhail Roshal, Tak Takvorian, Daneal Portman, Anthony R. Mato, Krista J Scorsune, Jason Carter, Ahmet Dogan, Lauren Ramos, Ai Ni, Natascha Nolet, Juliana M.L. Biondo, Jane Huang, Ephraim P. Hochberg, Anita Kumar, Stephanie Hughes, Morgan Choma, M. Lia Palomba, Rosalba Martignetti, Ariela Noy, Jeffrey A. Barnes, Meghan C. Thompson, P. Connor Johnson, Jeremy S. Abramson, Connie Lee Batlevi, Julia M Lynch, Qun Wu, Chaya Friedman, Erel Joffe, Joanna Mi, Brianne McGree, Elizabeth Simkins, Venkatraman E. Seshan, Matthew J. Matasar, Kelsey Flaherty, Omar Abdel-Wahab, Lindsey E. Roeker, Andrew D. Zelenetz, Jacob D. Soumerai, Neena Mahajan
Publikováno v:
The Lancet Haematology. 8:e879-e890
Summary Background We hypothesised that combining zanubrutinib with obinutuzumab and venetoclax (BOVen) as an initial therapy for chronic lymphocytic leukaemia and small lymphocytic lymphoma would lead to high rates of undetectable minimal residual d
Autor:
Andrew R. Hsu, Pamela C Egan, Diana O. Treaba, Max Petersen, James N. Butera, Rabin Niroula, Adam J. Olszewski, Anna Chorzalska, Patrycja M. Dubielecka, John L. Reagan, Thomas A Ollila, Adam Zayac, John Vatkevich, Jordan Robison, Ilyas Sahin, Chelsea D. Mullins, Habibe Kurt, Allison P. Jacob
Publikováno v:
Blood Advances
Key Points The NGS-MRD assay detected clonotypic DNA in 100% of CSF samples from patients who had lymphoma with parenchymal CNS involvement.Clonotypic DNA in CSF was present in 36% of newly diagnosed aggressive lymphomas and was associated with a 29%
Autor:
Ilan R. Kirsch, Juliana Craig, Frederick L. Locke, Michael D. Jain, Allison P. Jacob, Lik Wee Lee, Jay Y. Spiegel, Matthew J. Frank, Ali Bukhari, Gursharan K. Claire, David B. Miklos, Katherine A. Kong, Aaron P. Rapoport, Erin Dean, Nasheed Hossain, Chelsea D. Mullins, Crystal L. Mackall, Saurabh Dahiya
Publikováno v:
J Clin Oncol
PURPOSE Although the majority of patients with relapsed or refractory large B-cell lymphoma respond to axicabtagene ciloleucel (axi-cel), only a minority of patients have durable remissions. This prospective multicenter study explored the prognostic
Autor:
Warren D. Reynolds, Bita Sahaf, Zachary Ehlinger, Steven A. Feldman, Matthew J. Frank, Andrew R. Rezvani, Surbhi Sidana, Jay Y. Spiegel, Allison P. Jacob, Lori Muffly, Kara L. Davis, Shabnum Patel, Jean Oak, Eric H. Yang, Ilan R. Kirsch, Robert Lowsky, Laura Johnston, Juliana Craig, John S. Tamaresis, Michael G. Ozawa, John H. Baird, Sheren F. Younes, David B. Miklos, Parveen Shiraz, Chelsea D. Mullins, Crystal L. Mackall, Robert S. Negrin, Liora M. Schultz, Wen-Kai Weng, Everett Meyer, Sally Arai, Yasodha Natkunam, Sneha Ramakrishna
Publikováno v:
Blood
The prognosis of patients with large B-cell lymphoma (LBCL) that progresses after treatment with chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CAR19) is poor. We report on the first 3 consecutive patients with autologous CAR19-refrac
Autor:
Allison P. Jacob, Cindy Varga, Mariateresa Fulciniti, Nikhil C. Munshi, Shayna Sarosiek, Vaishali Sanchorawala
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 11, Iss 6, Pp 1-4 (2021)
Blood Cancer Journal, Vol 11, Iss 6, Pp 1-4 (2021)
Autor:
Erik Yusko, Mark Roschewski, Stefania Pittaluga, Nicole Lucas, Milos D. Miljkovic, Christopher Melani, Elaine S. Jaffe, Allison P. Jacob, Wyndham H. Wilson, Rahul Lakhotia
Publikováno v:
Blood advances. 5(20)
Peripheral T-cell lymphomas (PTCLs) have marked biologic and clinical heterogeneity, which confounds treatment decisions. Advances in circulating tumor DNA (ctDNA) assays using next-generation sequencing (NGS) have improved the detection of molecular